Literature DB >> 34043986

CircHelz activates NLRP3 inflammasome to promote myocardial injury by sponging miR-133a-3p in mouse ischemic heart.

Yu Bian1, Ping Pang2, Xin Li3, Shuting Yu3, Xiuzhu Wang3, Kuiwu Liu3, Jiaming Ju4, Han Wu3, Yuelin Gao3, Qian Liu3, Yingqiong Jia3, Zhezhe Qu3, Xiaoqian Bi3, Zhongting Mei3, Xinda Yin3, Ning Wang5, Weijie Du6, Baofeng Yang7.   

Abstract

Myocardial infarction (MI)-induced the activation of NLRP3 inflammasome has been well known to aggravate myocardial injury and cardiac dysfunction by causing inflammation and pyroptosis in the heart. Circular RNAs (circRNAs) have been demonstrated to play critical roles in cardiovascular diseases. However, the functions and mechanisms of circRNAs in modulating cardiac inflammatory response and cardiomyocyte pyroptosis remain largely unknown. We revealed that circHelz, a novel circRNA transcribed from the helicase with zinc finger (Helz) gene, was significantly upregulated in both the ischemic myocardium of MI mouse and neonatal mouse ventricular cardiomyocytes (NMVCs) exposed to hypoxia. Overexpression of circHelz caused cardiomyocyte injury in NMVCs by activating the NLRP3 inflammasome and inducing pyroptosis, while circHelz silencing reduced these effects induced by hypoxia. Furthermore, knockdown of circHelz remarkably attenuated NLRP3 expression, decreased myocardial infarct size, pyroptosis, inflammation, and increased cardiac function in vivo after MI. Overexpression of miR-133a-3p in cardiomyocytes greatly prevented pyroptosis in the presence of hypoxia or circHelz by targeting NLRP3 in NMVCs. Mechanistically, circHelz functioned as an endogenous sponge for miR-133a-3p via suppressing its activity. Overall, our results demonstrate that circHelz causes myocardial injury by triggering the NLRP3 inflammasome-mediated pro-inflammatory response and subsequent pyroptosis in cardiomyocytes by inhibiting miR-133a-3p function. Therefore, interfering with circHelz/miR-133a-3p/NLRP3 axis might be a promising therapeutic approach for ischemic cardiac diseases.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  CircHelz; Myocardial infarction; NLRP3 inflammasome; Pyroptosis; miR-133a-3p

Mesh:

Substances:

Year:  2021        PMID: 34043986     DOI: 10.1016/j.yjmcc.2021.05.010

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  6 in total

Review 1.  Targeting Epigenetics and Non-coding RNAs in Myocardial Infarction: From Mechanisms to Therapeutics.

Authors:  Jinhong Chen; Zhichao Liu; Li Ma; Shengwei Gao; Huanjie Fu; Can Wang; Anmin Lu; Baohe Wang; Xufang Gu
Journal:  Front Genet       Date:  2021-12-20       Impact factor: 4.599

2.  lncRNA HAGLR modulates myocardial ischemia-reperfusion injury in mice through regulating miR-133a-3p/MAPK1 axis.

Authors:  Zi Wang; Wenqi Luo; Peng Zhong; Yifan Feng; Huaibin Wang
Journal:  Open Med (Wars)       Date:  2022-07-19

Review 3.  Non-coding RNAs in necroptosis, pyroptosis, and ferroptosis in cardiovascular diseases.

Authors:  Yuxi Cai; Yiwen Zhou; Zhangwang Li; Panpan Xia; Xinxi ChenFu; Ao Shi; Jing Zhang; Peng Yu
Journal:  Front Cardiovasc Med       Date:  2022-08-04

4.  miRNA Expression Is Increased in Serum from Patients with Semantic Variant Primary Progressive Aphasia.

Authors:  Maria Serpente; Laura Ghezzi; Chiara Fenoglio; Francesca R Buccellato; Giorgio G Fumagalli; Emanuela Rotondo; Marina Arcaro; Andrea Arighi; Daniela Galimberti
Journal:  Int J Mol Sci       Date:  2022-07-30       Impact factor: 6.208

5.  CircRNA circFADS2 is under-expressed in sepsis and protects lung cells from LPS-induced apoptosis by downregulating miR-133a.

Authors:  Fang Niu; Xiaofeng Liang; Jindi Ni; Zhuye Xia; Lijing Jiang; Hong Wang; Hongjie Liu; Guofeng Shen; Xiang Li
Journal:  J Inflamm (Lond)       Date:  2022-03-12       Impact factor: 4.981

6.  LuQi Formula Regulates NLRP3 Inflammasome to Relieve Myocardial-Infarction-Induced Cardiac Remodeling in Mice.

Authors:  Xiaoqing Zhang; Dandan Zhao; Jiling Feng; Xiaoli Yang; Zhenzhen Lan; Tao Yang; Xiaoni Kong; Huiyan Qu; Hua Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-28       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.